Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharmaceutical company. As highlighted by Globenewswire, this biotech stock will report its first-quarter 2026 financial results after the market closes on May 13, 2026. Management will then host a conference call for investors on May 14 to discuss the earnings report and business updates.
Wall Street analysts estimate an earnings per share (EPS) of -$0.14 for the quarter. Revenue is expected to be approximately $10.9 million. As highlighted by Zacks Investment Research, the market anticipates Aquestive Therapeutics will show a year-over-year increase in earnings on these higher revenues, despite the expected loss.
The company's current financial data shows a trailing Price-to-Earnings (P/E) ratio of -6.29. A negative P/E ratio means Aquestive Therapeutics has had negative earnings, or a net loss, over the past twelve months. This is also reflected in its negative earnings yield of -15.90%.
Aquestive Therapeutics also has a negative Debt-to-Equity ratio of -3.90, which points to negative shareholder equity. This happens when a company's total liabilities are greater than its total assets. Its Enterprise Value to Operating Cash Flow ratio is also negative at -8.38, showing negative cash flow from operations.
On a different note, the company's Price-to-Sales ratio is 9.63. More importantly, Aquestive Therapeutics maintains a healthy current ratio of 3.14. A current ratio above one suggests a company has enough short-term assets, like cash and inventory, to cover its short-term debts.
